ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+1.82%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$6.41B
AUM Growth
+$6.41B
(-13%)
Cap. Flow
-$502M
Cap. Flow
% of AUM
-7.83%
Top 10 Holdings %
Top 10 Hldgs %
70.9%
Holding
50
New
6
Increased
8
Reduced
13
Closed
4
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$50.4M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$48.4M |
| 3 |
Akero Therapeutics
AKRO
|
$28.1M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$26.7M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$25.6M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$317M |
| 2 |
argenx
ARGX
|
$130M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$102M |
| 4 |
Sarepta Therapeutics
SRPT
|
$73.1M |
| 5 |
Nuvalent
NUVL
|
$36.2M |
Sector Composition
| 1 | Healthcare | 99.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $810M | 12.63% | 7,000,000 | – | – |
|
2
United Therapeutics
UTHR
$13.8B
| $644M | 10.05% | 2,852,500 -57,499 | -2% | -$13M |
|
|
3
argenx
ARGX
$43.6B
| $492M | 7.67% | 1,000,000 -263,500 | -21% | -$130M |
|
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $488M | 7.61% | 4,025,000 -602,888 | -13% | -$73.1M |
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $423M | 6.59% | 11,111,111 | – | – |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $373M | 5.82% | 1,759,606 | – | – |
|
7
Ascendis Pharma
ASND
$11.8B
| $344M | 5.36% | 3,670,000 +89,445 | +2% | +$8.38M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $341M | 5.31% | 3,850,000 -150,000 | -4% | -$13.3M |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $333M | 5.2% | 27,400,000 | – | – |
|
10
Krystal Biotech
KRYS
$4.27B
| $298M | 4.64% | 2,565,555 +4,744 | +0.2% | +$550K |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $290M | 4.53% | 6,666,666 +1,111,111 | +20% | +$48.4M |
|
12
Madrigal Pharmaceuticals
MDGL
$9.76B
| $227M | 3.54% | 1,555,000 +39,849 | +3% | +$5.82M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $179M | 2.79% | 1,011,111 -93,889 | -8% | -$16.6M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $167M | 2.61% | 4,900,000 | – | – |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $154M | 2.4% | 10,300,000 | – | – |
|
16
MoonLake Immunotherapeutics
MLTX
$3.54B
| $114M | 1.78% | 1,999,999 +274,999 | +16% | +$15.7M |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $81.8M | 1.28% | 11,550,000 -505,000 | -4% | -$3.58M |
|
18
Roivant Sciences
ROIV
$8.15B
| $54.3M | 0.85% | 4,651,162 -1,155,000 | -20% | -$13.5M |
|
19
Kymera Therapeutics
KYMR
$2.95B
| $53.6M | 0.84% | 3,855,000 | – | – |
|
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $53.5M | 0.83% | 1,500,000 +750,000 | +100% | +$26.7M |
|
|
21
Structure Therapeutics
GPCR
$1.11B
| $50.4M | 0.79% | +1,000,000 | New | +$50.4M |
|
|
22
Nuvalent
NUVL
$5.52B
| $37.4M | 0.58% | 812,500 -787,500 | -49% | -$36.2M |
|
23
MannKind Corp
MNKD
$1.41B
| $37.2M | 0.58% | 9,000,000 -100,000 | -1% | -$413K |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $37.1M | 0.58% | 2,555,555 -94,445 | -4% | -$1.37M |
|
25
Iovance Biotherapeutics
IOVA
$807M
| $30.5M | 0.48% | 6,700,000 | – | – |
|